Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US89422G1076
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG000P9D6W9
TVTX
Travere Therapeutics Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Travere Therapeutics Inc
ISIN
US89422G1076
TICKER
TVTX
MIC
XNAS
REUTERS
TVTX.OQ
BLOOMBERG
TVTX US
Wed, 10.09.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that following further review of the supplemental New Drug Application (sNDA) for FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS), an advisory committee is no longer needed. The sNDA remains under...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 03.09.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company shared two oral presentations in classical homocystinuria (HCU) at the International Congress of Inborn Errors of Metabolism, taking place September 2-6 in Kyoto, Japan. New long-term data from Cohort 6 of the Phase 1/2 COMPOSE open-label extension (OLE) Study demonstrat...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 27.08.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has approved updated Risk Evaluation and Mitigation Strategy (REMS) labeling for FILSPARI® (sparsentan), the only Dual Endothelin Angiotensin Receptor Antagonist for the treatment of IgA nephropathy (IgAN). The update reduces the frequency o...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 30.07.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report second quarter 2025 financial results on Wednesday, August 6, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dia...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 11.07.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on July 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 17 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 121,700 shares of its common stock. These inducement RSUs are subject to the t...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 02.07.2025       Travere Therapeutics
US89422G1076

NEW YORK, July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 22.06.2025       Travere Therapeutics
US89422G1076

NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.06.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on June 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 15 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 81,100 shares of its common stock. These inducement RSUs are subject to the te...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.06.2025       Travere Therapeutics
US89422G1076

NEW YORK, June 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 11.06.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present three abstracts on the effect of FILSPARI (sparsentan) in rare kidney disease at the upcoming International Podocyte Conference in Hamburg, Germany, June 10-13, 2025. The Company will present new data evaluating biomarkers of disease progression in IgA nephr...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 10.06.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the launch of a new awareness campaign, “Play It Forward,” to bring hope and encouragement to the focal segmental glomerulosclerosis (FSGS) community. FSGS is a rare kidney disease (RKD) affecting children and adults and a leading cause of kidney failure. This press release features multim...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 07.06.2025       Travere Therapeutics
US89422G1076

NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.06.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present seven abstracts at the upcoming European Renal Association (ERA) Congress in Vienna, Austria, June 4-7. Presentations will include new data on the use of FILSPARI in IgA nephropathy (IgAN) from the Phase 2 SPARTACUS Study which demonstrated that FILSPARI pro...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 01.06.2025       Travere Therapeutics
US89422G1076

NEW YORK, June 1, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 26.05.2025       Travere Therapeutics
US89422G1076

NEW YORK, May 26, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 21.05.2025       Travere Therapeutics
US89422G1076

NEW YORK, May 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 15.05.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for traditional approval of FILSPARI (sparsentan) for the treatment of focal segmental glomerulosclerosis (FSGS). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target a...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 12.05.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 35,900 shares of its common stock. These inducement RSUs are subject to the te...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 07.05.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA Securities 2025 Healthcare Conference Presenting on Wednesday, May 14, 2025, at 3:40 p.m. PT Jefferies Global Healthcare Conference Presenting on Wednesday, June 4, 2025, at 3:10 p.m. ET Scotiab...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 01.05.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2025 financial results and provided a corporate update. “As the only fully approved, kidney-targeted therapy that has demonstrated superior efficacy in a head-to-head trial, FILSPARI is elevating the standard of care in IgAN. Our strong start to the year reflects this lead...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Tue, 29.04.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor are pleased to announce that the European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard marketing authorization (MA) for FILSPARI for the treatment of adults with primary IgA nephropathy with a urine protein excretion ≥1.0 g/day (or urine...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 24.04.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2025 financial results on Thursday, May 1, 2025, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in i...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 11.04.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on April 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 31,100 shares of its common stock. These inducement RSUs are subject to the...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 31.03.2025       Travere Therapeutics
US89422G1076

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present three abstracts, including one late-breaking oral presentation, at the upcoming National Kidney Foundation (NKF) Spring Clinical Meetings 2025, taking place April 10-13 in Boston, MA. The late-breaking oral presentation will feature new analyses from the Phas...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 17.03.2025       Travere Therapeutics
US89422G1076

Travere announces sNDA submission to FDA based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS, a rare kidney condition....
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.03.2025       Travere Therapeutics
US89422G1076

SAN DIEGO, March 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 77,200 shares of its common stock to five new employees, consisting of inducement stock options to purchase...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 12.02.2025       Travere Therapeutics
US89422G1076

SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on February 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 115,100 shares of its common stock to ten new employees, consisting of inducement stock options to pur...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 11.02.2025       Travere Therapeutics
US89422G1076

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.01.2025       Travere Therapeutics
US89422G1076

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 8:15 a.m. PT....
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 25.11.2024       Travere Therapeutics
US89422G1076

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in December:...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 19.11.2024       Travere Therapeutics
US89422G1076

NEW YORK, Nov. 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.  ...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 13.11.2024       Travere Therapeutics
US89422G1076

SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 24,400 shares of its commo...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sun, 10.11.2024       Travere Therapeutics
US89422G1076

NEW YORK, Nov. 10, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.  ...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 08.11.2024       Travere Therapeutics
US89422G1076

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of $16.00 per share. All of the shares are being sold by Travere. The gross proceeds from the offering are expected to be $125.0 mill...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 02.11.2024       Travere Therapeutics
US89422G1076

NEW YORK, Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   ...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 31.10.2024       Travere Therapeutics
US89422G1076

FILSPARI® (sparsentan) received full FDA approval as the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Sat, 26.10.2024       Travere Therapeutics
US89422G1076

Travere presents data on FILSPARI (sparsentan) in IgAN and FSGS at ASN Kidney Week 2024....
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 25.10.2024       Travere Therapeutics
US89422G1076

NEW YORK, Oct. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.  ...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 21.10.2024       Travere Therapeutics
US89422G1076

SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2024 financial results on Thursday, October 31, 2024, before the open of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 17.10.2024       Travere Therapeutics
US89422G1076

NEW YORK, Oct. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.  ...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 14.10.2024       Travere Therapeutics
US89422G1076

Travere Therapeutics will present 11 abstracts, including one late-breaking abstract, at the upcoming ASN Kidney Week 2024 in San Diego....
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Fri, 11.10.2024       Travere Therapeutics
US89422G1076

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. (“Travere” or “the Company”) (NASDAQ: TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 10.10.2024       Travere Therapeutics
US89422G1076

NEW YORK, Oct. 10, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ: TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the invest...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 09.10.2024       Travere Therapeutics
US89422G1076

NEW YORK, Oct. 9, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.  ...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Wed, 02.10.2024       Travere Therapeutics
US89422G1076

NEW YORK, Oct. 2, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ: TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investi...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.09.2024       Travere Therapeutics
US89422G1076

SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on September 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 33,500 shares of its com...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 05.09.2024       Travere Therapeutics
US89422G1076

Travere Therapeutics announced that the U.S. FDA has granted full approval to FILSPARI® (sparsentan) to treat IgA nephropathy....
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Thu, 22.08.2024       Travere Therapeutics
US89422G1076

Travere today announced that it will present two posters in classical homocystinuria (HCU) at the SSIEM annual symposium....
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Mon, 08.07.2024       Travere Therapeutics
US89422G1076

Travere Therapeutics management will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on Monday, July 15, 2024, at 11:30 a.m. ET....
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink
Tue, 11.06.2024       Travere Therapeutics
US89422G1076

SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on June 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to three new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 10,500 shares of its common...
Read more
Travere Therapeutics
Technical Analysis Termsheets Terminal
Permalink